About the publication
Naming Safe TB-500
The name puts the hardest question over the door. The research has yet to answer it.
The word safe
Reassurance ahead of testing earns my immediate suspicion. With TB-500, the missing test is especially consequential: the fragment has no completed controlled human trial in the record here. Nearby evidence concerns full thymosin beta-4, including a human intravenous tolerability study and a substantial collection of cell and animal experiments.
Safe TB-500 exists because I want that safety claim examined closely. The name expresses the question that brought these pages together. It grants no clearance for anyone to use the substance. This is a publication about the research; its conclusions cannot assess a person’s health, and nothing here is medical advice.
The failed strength test
The mouse study that found extra regenerating fibers without stronger muscle reined in my enthusiasm about the repair mechanism. A tissue can look more active under examination while the animal’s function remains unimproved. That is an unusually useful disappointment.
The mechanism still intrigues me. The actin-binding structure is precise, and the rat wound results are substantial within their setting. The experimental leap to a confident human fragment claim earns my skepticism. The next persuasive result would measure the actual substance and the outcome being promised.
Publication boundaries
The site presents an examination of published research and the cited regulatory record. Personal treatment decisions require a licensed clinician who can assess the person involved. The contact page concerns errors in a claim or its source, and the references page retains the full reading list.
The experiments supply the material I want to examine: a precise molecular grip, repair signals, functional disappointments and a human safety question still waiting for its own test. An unsigned safety entry is the honest result of this inspection.